You need to enable JavaScript to run this app.
Recon: Gilead claims remdesivir reduced mortality in Phase 3 study; FDA staff flag ocular toxicities ahead of GSK myeloma drug panel
Recon
Michael Mezher
ReconMichael Mezher
ReconMichael Mezher